ARDECTO

Описание товара

About ARDECTO

ARDECTO is a prescription medication used to manage type 2 diabetes mellitus. It combines two active components, dapagliflozine propanodiol and saxagliptine, to improve glycemic control. The formulation is designed to be taken orally once daily, typically with breakfast. ARDECTO is manufactured under strict quality standards and is available in tablet form. The product is intended for use by adults with type 2 diabetes who require additional glucose lowering beyond diet and exercise. It is not indicated for type 1 diabetes or diabetic ketoacidosis. The medication is supplied in a blister pack containing 30 tablets, and the package includes a patient information leaflet that explains dosing, storage, and safety information. Patients should consult their healthcare provider before starting ARDECTO, especially if they have kidney disease, liver impairment, or a history of urinary tract infections. The drug is not recommended for use during pregnancy or lactation unless the benefits outweigh the risks. ARDECTO is part of a comprehensive diabetes management plan that may include lifestyle changes, monitoring of blood glucose, and other medications as prescribed by a clinician.

Key Benefits & Uses

• Improves blood glucose control in adults with type 2 diabetes.
• Provides dual mechanism of action through SGLT2 inhibition and DPP‑4 inhibition.
• Can be used as add‑on therapy to metformin or other antidiabetic agents.

Active Ingredient & Action

Dapagliflozine propanodiol is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. Saxagliptine is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor that prolongs the activity of incretin hormones, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. The combination of these two mechanisms provides complementary effects on glycemic regulation.

Important Notes

ARDECTO should be taken exactly as prescribed by a healthcare professional. Patients should monitor their blood glucose levels regularly and report any signs of hypoglycemia, urinary tract infection, or changes in kidney function to their clinician. The medication is not suitable for individuals with severe renal impairment or end-stage renal disease. Patients should avoid alcohol consumption while on ARDECTO, as it may increase the risk of dehydration and hypotension. The drug is not approved for use in children or adolescents. Storage should be at room temperature, away from moisture and direct sunlight. If a dose is missed, patients should take it as soon as remembered unless it is close to the next scheduled dose, in which case they should skip the missed dose and resume the regular schedule. For further information, patients should refer to the patient information leaflet provided with the medication.